Lifeboat Foundation

Glioblastoma multiforme (GBM) is often difficult to treat due to an enzyme (endonuclease DFF40/CAD (Death Fragmentation Factor, 40 kDa subunit / Caspase-Activated DNase)). This enzyme, which is essential for degrading DNA during apoptosis, appears both downregulated and improperly located inside the tumour cells. The researchers observed that overexpression of the enzyme allows the glioblastoma cells to properly degrade their DNA content.

Glioblastoma is the most aggressive manifestation of brain tumours. Due to its high invasive capacity and uncontrolled, infiltrating growth, it is particularly difficult to manage. Currently, the treatment for this disease consists of a combination of surgery (when possible), radiation and chemotherapy. Although current therapy raises the overall survival of patients by around 15 months, it remains inefficient at eradicating tumour cells and, unfortunately, recurrences are another of this cancer’s characteristics.

A team of researchers from the Institute of Neuroscience at the UAB, together with the Hospital Universitari de Bellvitge — ICO, have identified a common molecular alteration in glioblastoma. The researchers observed that the cells of this type of tumour harbour a common intrinsic defect that prevents them from degrading their genetic material during apoptosis, the most important form of programmed cell death induced by radiotherapy and chemotherapy.

Continue reading “Biochemical alteration responsible for brain tumor resistance identified” »

Really a sad fact.

Los Angeles hospital pays $17,000 ransom to get its computer system unlocked. Expert says hackers find medical institutions as easy, profitable targets.

Read more

So, we’re now adding possible murder to the charges of hackers?.

The Hollywood Presbyterian Medical Center in Los Angeles paid a ransom of 17,000 U.S. dollars to hackers after two weeks of being shut out of their computer network. We talk to cyber security expert Jay Radcliffe about medical cyber vulnerabilities.

Read more

Overview.

What is the MMTP? The MMTP is an ambitious project, designed to radically speed up the rate of progress in the field of regenerative medicine and aging research.

The project is the brainchild of our parent organisation, The International Longevity Alliance, a nonprofit foundation for science advocacy and research. The testing and discovery of compounds and treatments to delay or stop the processes of aging is a slow affair, with very few high quality, high impact studies conducted each year.

Read more

A new chip designed for the brain is now wireless. Now that it is no longer connected using wires, will it compromise its accuracy?

The Nanyang Technological University in Singapore has developed a smart chip that can be used for neural implants in order to wirelessly transmit brain signals to the rest of the body with 95% accuracy. These neural implants, and the data that they register, are expected to help curtail symptoms of diseases like Parkinson’s, and they could also help paraplegic patients move their prosthetic limbs.

For operations, external devices can use the the 5mm by 5mm chip to receive and analyze data before sending back important details, instead of sending the entire data stream all at once. This drastically decreases its power consumption, making the tech far more viable.

Read more

Researchers have developed a functioning miniature replica of the human brain, composed of neurons and glial cells, to help study and better understand neurological diseases.

A tiny ball of brain cells may help researchers alleviate or treat neurological diseases.

These small cellular balls act like miniature versions of the human brain, mimicking various aspects of the actual brain that include sending pulses of electric signals akin to what happens in a thinking mind. This research was reported at the annual meeting of the American Association for the Advancement of Science in Washington.

Read more

The facts about the CRISPR Patent.

Xconomy San Francisco —

If you ask people who don’t follow biotech too closely what they know about CRISPR, you might get two answers: genetic editing and a big patent fight.

Continue reading “Caribou Bio’s New CRISPR Patent Isn’t About Gene Editing” »

New insights on GBM resistance markers.

A research team, with the participation of the University of Granada (UGR), has made some progress in determining the causes for glioblastoma multiforme (GBM), one of the most aggressive brain tumors known, to be resistant to the drugs currently used, which is one of the main limitations of its treatment. The results have been recently published in two articles in PlosOne magazine.

The researchers have proven that proteoglycans (the cells’ structural elements), called decorin (DCN) and lumican (LUM), could be decisive in the behavior and development of a resistance to the drugs used for treating glioblastoma multiforme, such as temozolamide (TMZ). In the other hand, they have laid bare that the inhibition of the transcription of some of the sub-units belonging to the mismatch-repair (MMR) complex, a system that analyzes and repairs DNA, could be responsible of the failure of current therapies against this kind of tumor.

Continue reading “GBM Treatment Discoveries: Why Select Drugs Might not Work” »

Absolutely; it will and that is the real danger in technology. This is why security roles will be increasingly in demand over the next 7 to 10 years.

Kaspersky director Marco Preuss looks at the future of biometric technology and bio-cybersecurity.

Read more